miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç° ¹× ¼­ºñ½ºº°, ±â¼úº°, ¿öÅ©Ç÷ο캰, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)
miRNA Sequencing And Assay Market Size, Share & Trends Analysis Report By Product & Service (Library Preparation Kits), By Technology, By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030
»óǰÄÚµå : 1376011
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2023³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, Àü ¼¼°è miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ ½ÃÀå ±Ô¸ð´Â 2023³âºÎÅÍ 2030³â±îÁö 13.3%ÀÇ CAGRÀ» ±â·ÏÇϸç 2030³â±îÁö 8¾ï 2,350¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¹¸¦ µé¾î, miRNA´Â ¾Ï(ÀڱðæºÎ¾Ï, ³­¼Ò¾Ï, À¯¹æ¾Ï), ÆÐÇ÷Áõ, ½ÉÇ÷°ü°è Áúȯ, ½Å°æ°è ÁúȯÀÇ ¿¹ÈÄ ¹× Áø´ÜÀÇ ¹ÙÀÌ¿À¸¶Ä¿·Î È¿À²ÀûÀ¸·Î »ç¿ëµÉ ¼ö ÀÖ´Ù´Â °ÍÀÌ ¿©·¯ Á¶»ç ¿¬±¸¿¡¼­ ¾ð±ÞµÇ°í ÀÖ½À´Ï´Ù. ÀÌó·³ miRNAÀÇ ¿°±â¼­¿­ ºÐ¼®Àº ÀÓ»ó ÁúȯÀÇ À¯ÀüÀÚ Á¶Àý ºÐ¼®¿¡ ¸¹ÀÌ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 3¿ù¿¡ ¹ßÇ¥µÈ ÇÁ·ÐƼ¾î½º(FRONTIERS)Áö¿¡ °ÔÀçµÈ ³í¹®¿¡¼­´Â Ç÷¾× ±â¹Ý miRNA ¹ÙÀÌ¿À¸¶Ä¿°¡ ³ú ±â¹Ý miRNA ¹ßÇö°úÀÇ »ó°ü°ü°è¿¡ »ç¿ëµÉ ¼ö ÀÖ´Ù°í ¾ð±ÞÇß½À´Ï´Ù.

COVID-19ÀÇ Àü¿°º´Àº Äڷγª¹ÙÀÌ·¯½ºÀÇ Á¸À縦 È®ÀÎÇϱâ À§ÇØ miRNAÀÇ »ç¿ëÀ» °­È­ÇßÀ¸¸ç, miRNA ¹ÙÀÌ¿À¸¶Ä¿´Â COVID-19ÀÇ ½É°¢¼ºÀ» ³ªÅ¸³»¸ç Áø´Ü¿¡ Àû¿ëµÉ ¼ö ÀÖÀ¸¸ç, miRNA´Â ¸é¿ª ¹ÝÀÀ, ¹ÙÀÌ·¯½º Áõ½Ä, °¨¿°µÈ ¼¼Æ÷ÀÇ º¹Á¦, ½ÉÇ÷°ü ±â´É Àå¾Ö¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ½ÉÇ÷°ü ±â´É Àå¾Ö¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ COVID-19 ȯÀڷκÎÅÍ Ã¤ÃëÇÑ Ç÷Àå¿¡´Â Ç×ü¿Í Ç×¹ÙÀÌ·¯½º miRNA°¡ dzºÎÇÏ°Ô ÇÔÀ¯µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ´Â COVID-19 °¨¿° ȯÀÚ Ä¡·á¿¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ¹ÙÀÌ·¯½º»Ó¸¸ ¾Æ´Ï¶ó ȯÀÚÀÇ miRNA ¼­¿­ ºÐ¼®¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

PerkinElmer Inc., Illumina, Inc. ¹× Qiagen°ú °°Àº À¯¸í ±â¾÷µéÀº ¿©·¯ ÀÓ»ó ÀÀ¿ë ºÐ¾ß¿¡ Çõ½ÅÀûÀÎ ½ÃÄö½Ì Á¦Ç°À» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌµé ±â¾÷Àº ¿¬±¸±â°ü°ú ¿©·¯ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê¸¦ ü°áÇÏ¿© ¿¬±¸ ¿¬±¸¿¡¼­ÀÇ ½ÃÄö½Ì ¾ÖÇø®ÄÉÀ̼ÇÀ» È®´ëÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Çѱ¹ÀÇ ¹ÙÀÌ¿ÀÁ¦¾à ±â¾÷ ¹ÙÀÌ¿Àü½ºÆ®¶ó´Â 2022³â 1¿ù SK¹ÙÀÌ¿ÀÆÊ°ú Á¦ÈÞ °è¾àÀ» ü°áÇϰí miRNA¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â »õ·Î¿î Ä¡·á È­ÇÕ¹°ÀÇ ¿¬±¸°³¹ßÀ» °¡¼ÓÈ­Çß½À´Ï´Ù.

½ÃÀåÀÇ ÁÖ¿ä ¾÷üµéÀº ³ôÀº ƯÀ̼º°ú ÀçÇö¼ºÀ» °®Ãá »õ·Î¿î µµ±¸, Àåºñ ¹× ŰƮ °³¹ß¿¡ Âü¿©Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2019³â 10¿ù TriLink BioTechnologies´Â CleanTag ŰƮ¿ë ÇÁ¶óÀÌ¸Ó ¼¼Æ® 2Á¾À» Ãâ½ÃÇß½À´Ï´Ù. Thermo Fisher ScientificÀÇ ½ÃÄö¼­ Ç÷§ÆûÀº ÀÌ »õ·Î¿î Ion Torrent Convert ¹ÙÄÚµå ÇÁ¶óÀÌ¸Ó ¼¼Æ®¸¦ »ç¿ëÇÏ¿© ¼ÒºÐÀÚ RNA ¶óÀ̺귯¸®¸¦ ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãâ½Ã´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®:

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

Á¦4Àå miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ : Á¦Ç°°ú ¼­ºñ½º ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ : ±â¼ú ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ : ¿öÅ©Ç÷οì ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦9Àå miRNA ½ÃÄö½Ì ¹× ¾î¼¼ÀÌ : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦10Àå °æÀï »óȲ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

miRNA Sequencing And Assay Market Growth & Trends:

The global miRNA sequencing and assay market size is expected to reach USD 823.5 Million by 2030, registering a CAGR of 13.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. For instance, various research studies stated that miRNAs can be efficiently used as biomarkers in the prognosis and diagnosis of cancer (cervical, ovarian, and breast), sepsis, cardiovascular diseases, and nervous system conditions. Thus, miRNA sequence analysis is significantly employed for gene regulation analysis in clinical disorders. For instance, an article published in frontiers, in March 2022, stated that blood-based miRNA biomarkers could be used to correlate brain-based miRNA expression.

The COVID-19 pandemic has enhanced the usage of miRNA to identify the presence of coronavirus. miRNA biomarkers have potential application to indicate and diagnose the COVID-19 severity. It plays a significant role in immune response, viral proliferation, replication of infected cells, and cardiovascular dysfunction. In addition, plasma recovered from COVID-19 patients is rich in antibodies and antiviral miRNAs. It has been utilized to treat COVID-19-infected patients. This has resulted in increasing research studies that focus on the miRNA sequence analysis from the patient as well as the virus.

Prominent players such as PerkinElmer Inc.; Illumina, Inc.; and Qiagen offer innovative sequencing products for several clinical applications. Furthermore, these companies have entered into several strategic initiatives with research institutes to expand the sequencing application in research studies. For instance, in January 2022, BIORCHESTRA, a South Korean biopharmaceutical company, entered into a partnership agreement with SK Biopharmaceuticals to accelerate research and development into novel therapeutic compounds that target miRNAs.

Key market players are involved in the development of new tools, instruments, and kits with high specificity and reproducibility, which is fueling the market growth. For instance, in October 2019, TriLink BioTechnologies introduced two primer sets for its CleanTag kit. Thermo Fisher Scientific's sequencer platform can prepare small RNA libraries using these new Ion Torrent Convert barcode primer sets. Such launches are expected to boost market growth.

miRNA Sequencing And Assay Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. miRNA Sequencing And Assay Market Variables, Trends & Scope

Chapter 4. miRNA Sequencing And Assay: Product & Service Estimates & Trend Analysis

Chapter 5. MiRNA Sequencing And Assay: Technology Estimates & Trend Analysis

Chapter 6. MiRNA Sequencing And Assay: Workflow Estimates & Trend Analysis

Chapter 7. MiRNA Sequencing And Assay: Application Estimates & Trend Analysis

Chapter 8. MiRNA Sequencing And Assay: End Use Estimates & Trend Analysis

Chapter 9. MiRNA Sequencing And Assay: Regional Estimates & Trend Analysis

Chapter 10. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â